Identification | Back Directory | [Name]
Urea, N-(3,5-dichlorophenyl)-N′-(6-nitro-2-benzothiazolyl)- | [CAS]
2415653-55-1 | [Synonyms]
Urea, N-(3,5-dichlorophenyl)-N′-(6-nitro-2-benzothiazolyl)- | [Molecular Formula]
C14H8Cl2N4O3S | [MOL File]
2415653-55-1.mol | [Molecular Weight]
383.21 |
Chemical Properties | Back Directory | [density ]
1.722±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
6.80±0.70(predicted) | [color ]
Off-white to light yellow |
Hazard Information | Back Directory | [Uses]
CXCL-CXCR1/2-IN-1 is an orally active ELR+CXCL-CXCR1/2 pathway inhibitor with an EC50 of 42.7 nM for CXCR2[1]. CXCL-CXCR1/2-IN-1 shows anticancer and antiangiogenic effects[1]. | [in vivo]
CXCL-CXCR1/2-IN-1 (1 μM; 48 h) reduces metastasis area in zebrafish embryos injected with A498 cells[1].
CXCL-CXCR1/2-IN-1 (100 mg/kg; oral gavage; twice a day; for 28 days) inhibits tumor growth in mice[1]. Animal Model: | Female NOD SCID mice injected with 786 RCC cells[1] | Dosage: | 100 mg/kg | Administration: | Oral gavage; twice a day; for 28 days | Result: | Exhibited remarkable results, with a tumor growth inhibition rate of 87%.
|
| [References]
[1] Oleksandr Grytsai, et al. A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELR+CXCL-CXCR1/2 Pathway Inhibitor. ACS Med. Chem. Lett. April 3, 2024. |
|
|